作者
Thomas Boerner, Esther Drill, Linda M Pak, Bastien Nguyen, Carlie S Sigel, Alexandre Doussot, Paul Shin, Debra A Goldman, Mithat Gonen, Peter J Allen, Vinod P Balachandran, Andrea Cercek, James Harding, David B Solit, Nikolaus Schultz, Ritika Kundra, Henry Walch, Michael I D’Angelica, Ronald P DeMatteo, Jeffrey Drebin, Nancy E Kemeny, T Peter Kingham, Amber L Simpson, Jaclyn F Hechtman, Efsevia Vakiani, Maeve A Lowery, JNM Ijzermans, S Buettner, B Groot Koerkamp, M Doukas, Rohit Chandwani, William R Jarnagin
发表日期
2021/9
期刊
Hepatology
卷号
74
期号
3
页码范围
1429-1444
简介
Background and Aim
Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.
Approach and Results
This bi‐institutional study of patients with confirmed iCCA (n = 412) used targeted next‐generation sequencing of primary tumors to define associations among genetic alterations, clinicopathological variables, and outcome. The most common oncogenic alterations were isocitrate dehydrogenase 1 (IDH1; 20%), AT‐rich interactive domain–containing protein 1A (20%), tumor protein P53 (TP53; 17%), cyclin‐dependent kinase inhibitor 2A (CDKN2A; 15%), breast cancer 1–associated protein 1 (15%), FGFR2 (15%), polybromo 1 (12%), and KRAS (10%). IDH1/2 mutations (mut) were mutually exclusive with FGFR2 fusions, but neither was associated with outcome. For all patients, TP53 (P < 0.0001), KRAS (P = 0 …
学术搜索中的文章
T Boerner, E Drill, LM Pak, B Nguyen, CS Sigel… - Hepatology, 2021